Johnson & Johnsonvs.Zoetis
JNJ vs ZTS · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Johnson & Johnson is about 21× larger than Zoetis by market cap; Zoetis trades at the lower P/E (11.5 vs 29.9); year to date, Johnson & Johnson leads (+31.9% vs −38.7%).
Side by side
| JNJ | ZTS | |
|---|---|---|
| Market cap | $630B | $30.2B |
| Price | $273.14 | $77.29 |
| Today | +0.0% | +0.2% |
| Return YTD | +31.9% | −38.7% |
| Return 1Y | +52.3% | −50.7% |
| P/E | 29.9 | 11.5 |
| P/S | 6.4 | 3.2 |
| P/B | 7.4 | 9.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Johnson & JohnsonJNJ
Two businesses under one name: Innovative Medicine, which covers immunology and oncology drugs, and MedTech, which makes medical devices and surgical equipment.
Full JNJ profile →ZoetisZTS
Spun out of Pfizer in 2013 to sell animal medicines and vaccines. Simparica handles parasites while Librela and Solensia treat pain, with pets on one side of the business and livestock on the other.
Full ZTS profile →More JNJ & ZTS comparisons
Other head-to-heads in the Big pharma segment.